人附睾分泌蛋白4、糖链多肽抗原125联合卵巢恶性肿瘤风险预测模型对上皮性卵巢癌预测和诊断价值

发布时间：2018-06-06 01:04

本文选题：上皮性卵巢癌 + 人附睾分泌蛋白　；参考：《中国实用妇科与产科杂志》2015年07期

【摘要】：目的探讨血清中肿瘤标志物人附睾分泌蛋白4(HE4)、糖链多肽抗原125(CA125)和卵巢恶性肿瘤风险预测模型(ROMA)预测和诊断上皮性卵巢癌的临床价值。方法回顾性分析于2012年1月至2014年4月天津市中心妇产科医院因盆腔肿物就诊的225例病人,其中卵巢上皮癌113例,卵巢良性肿瘤112例,因体检来院的健康妇女33例。采用电化学发光法测定受试者术前血清HE4和CA125浓度,用卵巢风险评估模型计算ROMA指数。结果卵巢癌组CA125、HE4及ROMA值高于卵巢良性肿瘤组和健康对照组,差异均有统计学意义(P0.05)。卵巢良性肿瘤组CA125、HE4及ROMA值与健康对照组比较,差异无统计学意义(P0.05)。HE4、CA125、ROMA值诊断卵巢恶性肿瘤的敏感度分别为52.21%、85.84%、86.73%,特异度分别为100%、88.39%、83.93%,三者相比较,ROMA值的敏感度最好,HE4特异度最好。ROMA值绝经前后敏感度分别为85.71%和69.77%,特异度分别为86.90%和75%。结论HE4作为一种新型肿瘤标志物,其在卵巢上皮性癌中具有重要的诊断价值,而ROMA值预测患卵巢癌风险的敏感度较CA125、HE4二者单项高,有助于帮助临床医生评估患卵巢上皮性癌的风险性。
[Abstract]:Objective to evaluate the clinical value of serum tumor markers human epididymal secreting protein 4He-4H, carbohydrate polypeptide antigen 125 CA125) and ovarian malignant tumor risk prediction model (ROMA) in the prediction and diagnosis of epithelial ovarian cancer (EOC). Methods from January 2012 to April 2014, 225 patients with pelvic masses in Tianjin Center Obstetrics and Gynecology Hospital were retrospectively analyzed, including 113 cases of epithelial ovarian carcinoma, 112 cases of benign ovarian tumor, and 33 cases of healthy women who came to the hospital because of physical examination. Serum HE4 and CA125 concentrations were measured by electrochemiluminescence (ECL) and ROMA index was calculated by ovarian risk assessment model. Results the values of CA125 HE4 and ROMA in ovarian cancer group were higher than those in benign ovarian tumor group and healthy control group (P 0.05). The values of CA125, HE4 and ROMA in benign ovarian tumor group were compared with those in healthy control group. There was no significant difference in the sensitivity of P0.05, HE4, CA125U and ROMA in the diagnosis of ovarian malignant tumors. The sensitivity was 52.21 and 85.84, and the specificity was 86.73 and the specificity was 100 88.399.93, respectively. The best sensitivity of HE4 was 85.71% and 69.77% before and after menopause, and the specificity was 86.90% and 75m respectively. Conclusion as a new tumor marker, HE4 has an important diagnostic value in epithelial ovarian carcinoma. The sensitivity of ROMA in predicting the risk of ovarian cancer is higher than that of CA125 and HE4. Helps clinicians assess the risk of epithelial ovarian cancer.
【作者单位】：天津市中心妇产科医院;天津医科大学;
【分类号】：R737.31

【参考文献】